Through cholesterol reduction and disruption of the FAK/PI3K/Akt/mTOR signalling pathway, SQLE inhibition using FR194738 offered a promising therapeutic avenue, representing a potential supplementary treatment for high‐risk OSA patients. Here, SQLE is linked to obstructive sleep apnea syndrome.